Regeneron Pharmaceuticals, Inc. (REGN) Shares Sold by Van ECK Associates Corp

Van ECK Associates Corp trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 66,887 shares of the biopharmaceutical company’s stock after selling 14,536 shares during the quarter. Van ECK Associates Corp owned 0.06% of Regeneron Pharmaceuticals worth $32,851,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of REGN. BlackRock Inc. lifted its holdings in Regeneron Pharmaceuticals by 3,331.5% in the 1st quarter. BlackRock Inc. now owns 6,146,861 shares of the biopharmaceutical company’s stock valued at $2,381,971,000 after acquiring an additional 5,967,733 shares during the last quarter. Jennison Associates LLC lifted its stake in Regeneron Pharmaceuticals by 74.1% during the second quarter. Jennison Associates LLC now owns 1,292,863 shares of the biopharmaceutical company’s stock valued at $634,977,000 after buying an additional 550,247 shares in the last quarter. Janus Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 58.5% during the first quarter. Janus Capital Management LLC now owns 1,317,162 shares of the biopharmaceutical company’s stock valued at $510,406,000 after buying an additional 486,119 shares in the last quarter. Wellington Management Group LLP lifted its stake in Regeneron Pharmaceuticals by 7.9% during the first quarter. Wellington Management Group LLP now owns 6,135,559 shares of the biopharmaceutical company’s stock valued at $2,377,590,000 after buying an additional 446,850 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its stake in Regeneron Pharmaceuticals by 55.2% during the first quarter. Clearbridge Investments LLC now owns 690,254 shares of the biopharmaceutical company’s stock valued at $267,480,000 after buying an additional 245,531 shares in the last quarter. 67.94% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/21/regeneron-pharmaceuticals-inc-regn-shares-sold-by-van-eck-associates-corp.html.

A number of analysts have commented on the stock. Piper Jaffray Companies upped their price objective on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the company an “overweight” rating in a research note on Tuesday, June 20th. BMO Capital Markets set a $491.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $472.00 price objective (up from $469.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “hold” rating and set a $471.00 price objective (up from $418.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $580.00 price objective (up from $573.00) on shares of Regeneron Pharmaceuticals in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $491.43.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at 433.27 on Thursday. The firm’s 50-day moving average price is $468.97 and its 200 day moving average price is $447.18. The firm has a market cap of $45.94 billion, a P/E ratio of 43.47 and a beta of 1.65. Regeneron Pharmaceuticals, Inc. has a one year low of $325.35 and a one year high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The firm had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business’s quarterly revenue was up 21.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.82 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.89 EPS for the current year.

In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Robert E. Landry sold 663 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $498.60, for a total value of $330,571.80. Following the transaction, the senior vice president now directly owns 10,099 shares in the company, valued at approximately $5,035,361.40. The disclosure for this sale can be found here. Insiders have sold a total of 85,968 shares of company stock worth $40,699,948 in the last ninety days. Insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply